Compile Data Set for Download or QSAR
maximum 50k data
Found 548 with Last Name = 'morganelli' and Initial = 'pa'
TargetSolute carrier family 22 member 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM335495((2R,5S,13aR)—N-(2-chloro-4-fluorobenzyl)-8-hy...)
Affinity DataIC50:  42nMAssay Description:Test compounds were serially diluted in DMSO and then spiked (2 μL) into in 0.4 mL KHB buffer containing wild-type or OCT2-transfected cells and...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSolute carrier family 22 member 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM335495((2R,5S,13aR)—N-(2-chloro-4-fluorobenzyl)-8-hy...)
Affinity DataIC50:  42nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM335495((2R,5S,13aR)—N-(2-chloro-4-fluorobenzyl)-8-hy...)
Affinity DataIC50:  42nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM330054((2R,5S,13aR)-8-hydroxy-7,9-dioxo-N-(2,4,5-trifluor...)
Affinity DataIC50:  94nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSolute carrier family 22 member 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM330054((2R,5S,13aR)-8-hydroxy-7,9-dioxo-N-(2,4,5-trifluor...)
Affinity DataIC50:  94nMAssay Description:Test compounds were serially diluted in DMSO and then spiked (2 μL) into in 0.4 mL KHB buffer containing wild-type or OCT2-transfected cells and...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSolute carrier family 22 member 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM330054((2R,5S,13aR)-8-hydroxy-7,9-dioxo-N-(2,4,5-trifluor...)
Affinity DataIC50:  94nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSolute carrier family 22 member 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM335491((13aS)-8-hydroxy-7,9-dioxo-N-(2,4,6-trifluorobenzy...)
Affinity DataIC50:  137nMAssay Description:Test compounds were serially diluted in DMSO and then spiked (2 μL) into in 0.4 mL KHB buffer containing wild-type or OCT2-transfected cells and...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSolute carrier family 22 member 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM589177(US11548901, Compound 45)
Affinity DataIC50:  137nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM330049((13aS)-8-hydroxy-7,9-dioxo-N-(2,4,6-trifluorobenzy...)
Affinity DataIC50:  137nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSolute carrier family 22 member 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM335488(US11548901, Compound 40 | US9732092, Compound 40)
Affinity DataIC50:  204nMAssay Description:Test compounds were serially diluted in DMSO and then spiked (2 μL) into in 0.4 mL KHB buffer containing wild-type or OCT2-transfected cells and...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM448201(US10689399, Compound 40)
Affinity DataIC50:  204nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSolute carrier family 22 member 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM335488(US11548901, Compound 40 | US9732092, Compound 40)
Affinity DataIC50:  204nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM350693(US9795602, Compound 29)
Affinity DataIC50:  216nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSolute carrier family 22 member 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM330039((2R,5S,13aR)-N-(2,4-difluorobenzyl)-8-hydroxy-7,9-...)
Affinity DataIC50:  240nMAssay Description:Test compounds were serially diluted in DMSO and then spiked (2 μL) into in 0.4 mL KHB buffer containing wild-type or OCT2-transfected cells and...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSolute carrier family 22 member 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM330039((2R,5S,13aR)-N-(2,4-difluorobenzyl)-8-hydroxy-7,9-...)
Affinity DataIC50:  240nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM330039((2R,5S,13aR)-N-(2,4-difluorobenzyl)-8-hydroxy-7,9-...)
Affinity DataIC50:  240nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSolute carrier family 22 member 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM330040((2S,5R,13aS)-N-(2,4-difluorobenzyl)-8-hydroxy-7,9-...)
Affinity DataIC50:  250nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSolute carrier family 22 member 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM335482(US9732092, Compound 3)
Affinity DataIC50:  250nMAssay Description:Test compounds were serially diluted in DMSO and then spiked (2 μL) into in 0.4 mL KHB buffer containing wild-type or OCT2-transfected cells and...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM330040((2S,5R,13aS)-N-(2,4-difluorobenzyl)-8-hydroxy-7,9-...)
Affinity DataIC50:  250nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSolute carrier family 22 member 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM335487(US11548901, Compound 39 | US9732092, Compound 39)
Affinity DataIC50:  358nMAssay Description:Test compounds were serially diluted in DMSO and then spiked (2 μL) into in 0.4 mL KHB buffer containing wild-type or OCT2-transfected cells and...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSolute carrier family 22 member 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM335487(US11548901, Compound 39 | US9732092, Compound 39)
Affinity DataIC50:  358nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM448200(US10689399, Compound 39)
Affinity DataIC50:  358nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSolute carrier family 22 member 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM335503((1R,4R,12aS)-N-(2,4-difluorobenzyl)-7-hydroxy-6,8-...)
Affinity DataIC50:  450nMAssay Description:Test compounds were serially diluted in DMSO and then spiked (2 μL) into in 0.4 mL KHB buffer containing wild-type or OCT2-transfected cells and...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM448216(US10689399, Compound 100)
Affinity DataIC50:  450nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSolute carrier family 22 member 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM589189(US11548901, Compound 100)
Affinity DataIC50:  450nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSolute carrier family 22 member 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM330052((1R,4S,12aS)-7-hydroxy-6,8-dioxo-N-(2,4,6-trifluor...)
Affinity DataIC50:  476nMAssay Description:Test compounds were serially diluted in DMSO and then spiked (2 μL) into in 0.4 mL KHB buffer containing wild-type or OCT2-transfected cells and...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSolute carrier family 22 member 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM330052((1R,4S,12aS)-7-hydroxy-6,8-dioxo-N-(2,4,6-trifluor...)
Affinity DataIC50:  476nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM330052((1R,4S,12aS)-7-hydroxy-6,8-dioxo-N-(2,4,6-trifluor...)
Affinity DataIC50:  476nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSolute carrier family 22 member 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM335490((2R,5S,13aR)-8-hydroxy-7,9-dioxo-N-(2,4,6-trifluor...)
Affinity DataIC50:  487nMAssay Description:Test compounds were serially diluted in DMSO and then spiked (2 μL) into in 0.4 mL KHB buffer containing wild-type or OCT2-transfected cells and...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM330048((2R,5S,13aR)-8-hydroxy-7,9-dioxo-N-(2,4,6-trifluor...)
Affinity DataIC50:  487nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSolute carrier family 22 member 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM330048((2R,5S,13aR)-8-hydroxy-7,9-dioxo-N-(2,4,6-trifluor...)
Affinity DataIC50:  487nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM448198(US10689399, Compound 13)
Affinity DataIC50:  610nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSolute carrier family 22 member 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM330043((2S,5R,13aS)-N—((S)-1-(2,4-difluorophenyl)eth...)
Affinity DataIC50:  610nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSolute carrier family 22 member 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM330043((2S,5R,13aS)-N—((S)-1-(2,4-difluorophenyl)eth...)
Affinity DataIC50:  610nMAssay Description:Test compounds were serially diluted in DMSO and then spiked (2 μL) into in 0.4 mL KHB buffer containing wild-type or OCT2-transfected cells and...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSolute carrier family 22 member 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM589186(US11548901, Compound 96)
Affinity DataIC50:  1.36E+3nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSolute carrier family 22 member 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM335500((1R,3R,11aS)-6-hydroxy-5,7-dioxo-N-(2,4,6-trifluor...)
Affinity DataIC50:  1.36E+3nMAssay Description:Test compounds were serially diluted in DMSO and then spiked (2 μL) into in 0.4 mL KHB buffer containing wild-type or OCT2-transfected cells and...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM448213(US10689399, Compound 96)
Affinity DataIC50:  1.36E+3nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSolute carrier family 22 member 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM330060((1R,3S,4R,12aR)-7-hydroxy-3-methyl-6,8-dioxo-N-(2,...)
Affinity DataIC50:  1.51E+3nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM330060((1R,3S,4R,12aR)-7-hydroxy-3-methyl-6,8-dioxo-N-(2,...)
Affinity DataIC50:  1.51E+3nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSolute carrier family 22 member 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM330060((1R,3S,4R,12aR)-7-hydroxy-3-methyl-6,8-dioxo-N-(2,...)
Affinity DataIC50:  1.51E+3nMAssay Description:Test compounds were serially diluted in DMSO and then spiked (2 μL) into in 0.4 mL KHB buffer containing wild-type or OCT2-transfected cells and...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSolute carrier family 22 member 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM330041( (4R,12aS)-N-(1-(2,4-difluorophenyl)cyclopropyl)-7...)
Affinity DataIC50:  2.23E+3nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM330041( (4R,12aS)-N-(1-(2,4-difluorophenyl)cyclopropyl)-7...)
Affinity DataIC50:  2.23E+3nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSolute carrier family 22 member 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM335483(US9732092, Compound 5)
Affinity DataIC50:  2.23E+3nMAssay Description:Test compounds were serially diluted in DMSO and then spiked (2 μL) into in 0.4 mL KHB buffer containing wild-type or OCT2-transfected cells and...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM350694(US9795602, Compound 58)
Affinity DataIC50:  2.49E+3nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM350830(US9795602, Compound 59)
Affinity DataIC50:  2.51E+3nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSolute carrier family 22 member 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM330047((1R,4S,12aR)-7-hydroxy-6,8-dioxo-N-(2,4,6-trifluor...)
Affinity DataIC50:  2.82E+3nMAssay Description:Test compounds were serially diluted in DMSO and then spiked (2 μL) into in 0.4 mL KHB buffer containing wild-type or OCT2-transfected cells and...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM330047((1R,4S,12aR)-7-hydroxy-6,8-dioxo-N-(2,4,6-trifluor...)
Affinity DataIC50:  2.82E+3nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSolute carrier family 22 member 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM330047((1R,4S,12aR)-7-hydroxy-6,8-dioxo-N-(2,4,6-trifluor...)
Affinity DataIC50:  2.82E+3nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSolute carrier family 22 member 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM330059((1S,4R,12aR)-3,3-difluoro-7-hydroxy-6,8-dioxo-N-(2...)
Affinity DataIC50:  3.73E+3nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences

US Patent
LigandPNGBDBM330059((1S,4R,12aR)-3,3-difluoro-7-hydroxy-6,8-dioxo-N-(2...)
Affinity DataIC50:  3.73E+3nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 548 total ) | Next | Last >>
Jump to: